#South Korea #Seoul #LOTTE BIOLOGICS #ADC Manufacturing #Bio Campus

LOTTE BIOLOGICS Launches ADC Manufacturing Facility

LOTTE BIOLOGICS, led by CEO James Park, recently marked a significant milestone with the official launch of its Antibody-Drug Conjugate (ADC) manufacturing facility located at the Syracuse Bio Campus in New York. This pivotal moment for the company aligns with the signing of a manufacturing agreement with an Asia-based biotech firm to produce a clinical-stage ADC candidate, signifying the commencement of its contract development and manufacturing organization (CDMO) services.

The ADC manufacturing facility, which began construction in 2023, has been designed to offer comprehensive support for clients ranging from clinical development to large-scale production. This facility is more than just a construction project; it represents an investment of approximately USD $100 million, ensuring compliance with current Good Manufacturing Practices (cGMP).

Features of the ADC Manufacturing Facility

The facility boasts an integrated production and purification line, including a conjugation reactor that can handle capacities of up to 1,000 liters. This integrated approach ensures that all phases of production, from antibody preprocessing to the automated aseptic filling of drug substances, can be performed with flexibility and efficiency. Additionally, the facility includes robust in-house quality control (QC) testing capabilities and advanced characterization services, enabling LOTTE BIOLOGICS to meet diverse client needs effectively.

CEO James Park expressed optimism regarding the future of the company, stating that this contract with the Asia-based biotech firm lays the foundation for a stable supply of high-quality ADC therapeutics. He emphasized the company’s commitment not only to act as a manufacturer of antibodies but to solidify its reputation as a specialized CDMO in the ADC space. He also mentioned that the company is keen on pursuing additional collaboration opportunities to enhance its position in this competitive business sector.

The ribbon-cutting ceremony for the new facility was attended by notable figures including James Park, the head of global strategy, and other key personnel, celebrating the completion of a project that underscores LOTTE BIOLOGICS’ commitment to innovation and excellence in biotechnology.

Future Plans

Looking toward the future, LOTTE BIOLOGICS plans to expand its operations significantly. The company is in the process of constructing three advanced biopharmaceutical plants in Songdo, South Korea, with expectations for the first facility to become operational by 2027. Each of these new facilities will be equipped with eight 15,000-liter stainless steel bioreactors, coupled with multiple 2,000-liter single-use bioreactors, which will collectively allow for a manufacturing volume exceeding 360,000 liters.

This expansion will position LOTTE BIOLOGICS not only as a leader in the ADC sector but also as a well-rounded player in the global biotechnology landscape. With an eye toward harnessing the potential of ADCs, the firm is set to redefine standards in the industry, ensuring that it meets the increasing demands for advanced cancer therapies across the globe.

LOTTE BIOLOGICS, founded in 2022 and headquartered in Seoul, South Korea, operates with a vision of delivering innovative therapies that contribute positively to global health. The Syracuse Bio Campus underlines this vision by providing top-tier GMP manufacturing services for drug substances, allowing the company to serve as an essential player in the biotechnology field.

For more details about LOTTE BIOLOGICS and its services, visit www.lottebiologics.com.